BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 21270815)

  • 21. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
    Naseratun N; Kobara M; Watanabe Y; Toba H; Nakata T
    Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1545-1553. PubMed ID: 32323339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
    Wada T; Kanagawa R; Ishimura Y; Inada Y; Nishikawa K
    J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.
    Konda T; Enomoto A; Takahara A; Yamamoto H
    Biol Pharm Bull; 2006 May; 29(5):933-7. PubMed ID: 16651722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
    Aritomi S; Koganei H; Wagatsuma H; Mitsui A; Ogawa T; Nitta K; Konda T
    Heart Vessels; 2010 Nov; 25(6):549-55. PubMed ID: 20922532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
    Karam H; Clozel JP; Bruneval P; Gonzalez MF; Ménard J
    Hypertension; 1999 Oct; 34(4 Pt 1):673-8. PubMed ID: 10523345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
    Konda T; Enomoto A; Matsushita J; Takahara A; Moriyama T
    Nephron Physiol; 2005; 101(1):p1-13. PubMed ID: 15886499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T; Ueno M; Tominaga M; Kajioka T; Onaka U; Eto K; Goto K
    Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
    Brown L; Duce B; Miric G; Sernia C
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of an N-type calcium antagonist on angiotensin II-renin feedback.
    Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
    Am J Nephrol; 2011; 33(2):168-75. PubMed ID: 21293118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists.
    Nap A; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2004 Jun; 18(3):309-19. PubMed ID: 15147282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
    Seino H; Miyaguchi S; Yamazaki T; Ota S; Yabe R; Suzuki S
    Arzneimittelforschung; 2007; 57(8):526-31. PubMed ID: 17915639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic effects of an N- and L-type Ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats.
    Takemori K; Ishida H; Dote K; Yamamoto K; Ito H
    Can J Physiol Pharmacol; 2005; 83(8-9):785-90. PubMed ID: 16333380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the L/N-Type Ca
    Harada E; Sugino K; Aimoto M; Takahara A
    Biol Pharm Bull; 2021 May; 44(5):707-713. PubMed ID: 33642455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.
    Aritomi S; Konda T; Yoshimura M
    Heart Vessels; 2012 Jul; 27(4):419-23. PubMed ID: 21989861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.